Weekly somatrogon noninferior to daily somatropin in growth hormone deficiency

The efficacy of once-weekly somatrogon was comparable to once-daily somatropin in prepubertal children with growth hormone deficiency (GHD), according to a study.

In this phase 3, open-label, randomized trial, children with GHD were randomized 1:1 to receive once-weekly somatrogon (n = 109) or once-daily somatropin (n = 115) for 12 months. The primary endpoint was annualized height velocity (HV) at month 12.

At 12 months, HV in the somatrogon-treated group and the somatropin-treated group was 10.10 cm/year and 9.78 cm/year, respectively. There was a treatment difference of 0.33 (95% CI: -0.24, 0.89).

Mild to moderate treatment-emergent adverse events were similar between the groups with 78.9% of patients in the somatrogon group experiencing them and 79.1% in the somatropin group.

Reference
Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. J Clin Endocrinol Metab. 2022;107(7):e2717-e2728. doi: 10.1210/clinem/dgac220. PMID: 35405011; PMCID: PMC9202717.